Universität Rostock, 2015
Abstract: From 1/3/2009 to 1/3/2012, 1158 patients were diagnosed of lung cancers at Cho Ray hospital, included adenocarcinoma (64.3%), squamous cell carcinoma (11.3%), small cell (4.9%) and others. In NSCLC, 38.4% were in stage III and 60 (14.2%)were selected to receive weekly Paclitaxel–Carboplatin concurrently with chest radiotherapy. Common severe toxicities included esophagitis (23.3%) and fatigue (23.3%). Response rate was 57.2%; median of overall and progression-free survival were 14.4 and 10.8 months. Pretreatment performance status and weight loss were two only significant prognostic factors.
doctoral thesis free access